First Quadrant L P CA trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 17.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 40,404 shares of the medical research company’s stock after selling 8,487 shares during the quarter. Thermo Fisher Scientific accounts for approximately 0.8% of First Quadrant L P CA’s portfolio, making the stock its 18th biggest position. First Quadrant L P CA’s holdings in Thermo Fisher Scientific were worth $11,866,000 as of its most recent SEC filing.
Several other large investors have also modified their holdings of TMO. FMR LLC increased its position in shares of Thermo Fisher Scientific by 33.5% during the 1st quarter. FMR LLC now owns 11,572,581 shares of the medical research company’s stock worth $3,167,647,000 after purchasing an additional 2,900,868 shares during the last quarter. BlackRock Inc. grew its position in Thermo Fisher Scientific by 4.1% in the 1st quarter. BlackRock Inc. now owns 27,251,678 shares of the medical research company’s stock valued at $7,459,327,000 after acquiring an additional 1,074,400 shares in the last quarter. Marshall Wace LLP grew its position in Thermo Fisher Scientific by 361.8% in the 1st quarter. Marshall Wace LLP now owns 775,103 shares of the medical research company’s stock valued at $212,161,000 after acquiring an additional 607,245 shares in the last quarter. Geode Capital Management LLC grew its position in Thermo Fisher Scientific by 9.4% in the 4th quarter. Geode Capital Management LLC now owns 4,897,714 shares of the medical research company’s stock valued at $1,094,013,000 after acquiring an additional 422,625 shares in the last quarter. Finally, Swedbank acquired a new position in Thermo Fisher Scientific in the 1st quarter valued at about $111,710,000. 87.97% of the stock is owned by hedge funds and other institutional investors.
Shares of TMO traded down $2.99 during midday trading on Friday, hitting $274.82. The company had a trading volume of 2,096,269 shares, compared to its average volume of 1,393,107. The company has a 50-day moving average price of $291.36. The company has a quick ratio of 1.07, a current ratio of 1.49 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $111.12 billion, a price-to-earnings ratio of 24.71, a P/E/G ratio of 1.82 and a beta of 1.11. Thermo Fisher Scientific Inc. has a 1 year low of $208.34 and a 1 year high of $305.45.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Tuesday, September 17th will be paid a $0.19 dividend. This represents a $0.76 annualized dividend and a dividend yield of 0.28%. The ex-dividend date of this dividend is Monday, September 16th. Thermo Fisher Scientific’s payout ratio is presently 6.83%.
Several equities analysts have weighed in on TMO shares. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $299.00 target price for the company in a research report on Wednesday, June 12th. Barclays set a $330.00 target price on Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Monday, July 15th. Wolfe Research started coverage on Thermo Fisher Scientific in a research report on Thursday, May 30th. They issued an “outperform” rating for the company. BTIG Research lifted their target price on Thermo Fisher Scientific to $320.00 and gave the company a “buy” rating in a research report on Thursday, May 23rd. Finally, Bank of America reaffirmed a “buy” rating and issued a $300.00 target price (up from $285.00) on shares of Thermo Fisher Scientific in a research report on Tuesday, April 16th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Thermo Fisher Scientific has a consensus rating of “Buy” and a consensus price target of $303.17.
In other news, Director C Martin Harris sold 275 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $270.73, for a total value of $74,450.75. Following the completion of the transaction, the director now owns 6,433 shares in the company, valued at approximately $1,741,606.09. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 50,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, July 30th. The shares were sold at an average price of $284.83, for a total value of $14,241,500.00. Following the completion of the transaction, the chief executive officer now owns 342,193 shares of the company’s stock, valued at approximately $97,466,832.19. The disclosure for this sale can be found here. Insiders sold a total of 52,775 shares of company stock valued at $14,986,676 in the last quarter. Company insiders own 0.45% of the company’s stock.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Further Reading: What does a neutral rating on stocks mean?
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.